Meglumine gamma linolenate
Alternative Names: Megla; Meglumine gamma linolenic acid; Meglumine GLA; SC 101iLatest Information Update: 22 Jan 2002
At a glance
- Originator Scotia Pharmaceuticals [CEASED]
- Class Antineoplastics; Hexosamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer
Most Recent Events
- 22 Jan 2002 Discontinued-II for Bladder cancer in United Kingdom (Intratumoural)
- 19 Oct 2000 Phase-II clinical trials for Bladder cancer in United Kingdom (Intratumoural)
- 19 Oct 2000 A clinical study in patients with bladder cancer has been added to the adverse events and Cancer therapeutic trials sections